Navigation Links
Conatus Pharmaceuticals Initiates a Phase 2 Clinical Trial for the Treatment of Hepatitis
Date:12/20/2007

SAN DIEGO, Dec. 20 /PRNewswire/ -- Conatus Pharmaceuticals Inc. today announced the initiation of a clinical trial with a novel drug candidate for the treatment of liver disease associated with Hepatitis C Virus (HCV) infection in patients who have failed the approved standard of care treatments.

The oral, small molecule drug candidate, CTS-1027, is being studied as a treatment for the inflammatory damage to the liver resulting from infection by HCV. CTS-1027 inhibits the activity of key members of a class of protease enzymes, the matrix metalloproteinases or MMPs. In the liver and in other solid organs, MMPs play an important role in regulating inflammation as well as in maintaining the integrity of the extracellular matrix. CTS-1027 has been shown to be effective in multiple preclinical models of liver disease.

The clinical trial is a double-blind, placebo-controlled, multiple-dose trial lasting for four weeks followed by a voluntary open label period of up to eight additional weeks. The Company expects approximately 100 patients to be enrolled. The clinical trial will be conducted at up to ten medical centers in the U.S. Additional information about the trial can be found at http://www.clinicaltrials.gov (Identifier NCT00570336) or http://clinicaltrials.gov/ct2/show/NCT00570336?term=CTS-1027&rank=1.

"We are excited to initiate this proof of concept trial in HCV patients with CTS-1027," said Steven J. Mento, President and CEO of Conatus. "We believe that CTS-1027 represents a novel approach to treating liver inflammation and look forward to developing this drug candidate to fill an important medical need in HCV-infected patients."

Conatus Pharmaceuticals Inc. is a privately-held specialty pharmaceutical company engaged in the development of innovative human therapeutics to treat liver disease. Chronic liver disease affects millions of people worldwide and can be caused by many different conditions or "insults" to the liver including Hepatitis C and other viral infections, obesity, chronic alcohol abuse or autoimmune diseases. Conatus was founded by the executive management team of Idun Pharmaceuticals in July 2005 following the successful sale of Idun to Pfizer. For additional information, please visit http://www.conatuspharma.com.


'/>"/>
SOURCE Conatus Pharmaceuticals Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2017)... , ... August 21, 2017 , ... ... a leading Chinese bio security firm, to bring its proprietary CANARY pathogen detection ... of the relationship, the Chinese firm has purchased an undisclosed number of PathSensors’ ...
(Date:8/18/2017)... San Jose, CA (PRWEB) , ... August 18, ... ... of advanced precision Lithography Equipment for the Semiconductor, MEMS, and Microfluidics Industries, announces ... offers features and specifications found more often in automated production mask aligners. OAI ...
(Date:8/16/2017)... Linda, Ca (PRWEB) , ... August 16, 2017 ... ... treatment by changing into a different cell type. Many treatments for specific cancers, ... A prominent example of targeted treatment is androgen deprivation therapy for advanced prostate ...
(Date:8/16/2017)... , Aug. 16, 2017  Kingfisher Talent, the ... development, and Virdis Group, global executive search specialists in the ... enables clients to leverage the expertise and reach of both ... here in the Boston biotech hub, ... leadership talent throughout the US, Canada ...
Breaking Biology Technology:
(Date:5/16/2017)... May 16, 2017   Bridge Patient Portal ... and MD EMR Systems , an electronic ... for GE, have established a partnership to build ... and the GE Centricity™ products, including Centricity Practice ... These new integrations will allow healthcare ...
(Date:4/24/2017)... , April 24, 2017 Janice ... partner with  Identity Strategy Partners, LLP (IdSP) , ... or without President Trump,s March 6, 2017 ... Entry , refugee vetting can be instilled with greater ... (Right now, all refugee applications are suspended by ...
(Date:4/18/2017)... Calif. , April 18, 2017  Socionext Inc., a global ... of a media edge server, the M820, which features the company,s ... recognition software provided by Tera Probe, Inc., will be showcased during ... at the NAB show at the Las Vegas ... ...
Breaking Biology News(10 mins):